SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-010741
Filing Date
2024-03-21
Accepted
2024-03-21 08:50:38
Documents
16
Period of Report
2024-03-19
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 49260
2 ex99-1.htm EX-99.1 10721
3 ex99-1_001.jpg GRAPHIC 3899
  Complete submission text file 0001493152-24-010741.txt   284060

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ptix-20240319.xsd EX-101.SCH 3796
5 XBRL DEFINITION FILE ptix-20240319_def.xml EX-101.DEF 26655
6 XBRL LABEL FILE ptix-20240319_lab.xml EX-101.LAB 36749
7 XBRL PRESENTATION FILE ptix-20240319_pre.xml EX-101.PRE 25279
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5579
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

IRS No.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 24769625
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)